Functional characterization of human equilibrative nucleoside transporter 1

Abstract

Equilibrative nucleoside transporters (ENTs), which facilitate cross-membrane transport of nucleosides and nucleoside-derived drugs, play an important role in the salvage pathways of nucleotide synthesis, cancer chemotherapy, and treatment for virus infections. Functional characterization of ENTs at the molecular level remains technically challenging and hence scant. In this study, we report successful purification and biochemical characterization of human equilibrative nucleoside transporter 1 (hENT1) in vitro. The HEK293Fderived, recombinant hENT1 is homogenous and functionally active in proteoliposome-based counter flow assays. hENT1 transports the substrate adenosine with a Km of 215±34 μmol/L and a Vmax of 578±23.4 nmol mg−1 min−1. Adenosine uptake by hENT1 is competitively inhibited by nitrobenzylmercaptopurine ribonucleoside (NBMPR), nucleosides, deoxynucleosides, and nucleoside-derived anti-cancer and anti-viral drugs. Binding of hENT1 to adenosine, deoxyadenosine, and adenine by isothermal titration calorimetry is in general agreement with results of the competitive inhibition assays. These results validate hENT1 as a bona fide target for potential drug target and serve as a useful basis for future biophysical and structural studies.

Key words： hENT1; nucleoside; functional characterization; transport; counter flow

References

1 AseervathamJ, TranL, MachacaK, BoudkerO (2015) The role of flexible loops in folding, trafficking and activity of equilibrative nucleoside transporters. PLoS ONE10:e0136779

2 BaldwinSA, BealPR, YaoSYM, KingAE, CassCE, YoungJD (2004) The equilibrative nucleoside transporter family, SLC29. Pflug Arch447:735–743

3 BarnesK, DobrzynskiH, FoppoloS, BealPR, IsmatF, ScullionER, SunL, TellezJ,RitzelMW, ClaycombWC (2006) Distribution and functional characterization of equilibrative nucleoside transporter-4, a novel cardiac adenosine transporter activated at acidic pH. Circ Res99:510–519

4 BorbathI, VerbruggheL, LaiR, GigotJF, HumbletY, PiessevauxH, SempouxC (2012) Human equilibrative nucleoside transporter 1 (hENT1) expression is a potential predictive tool for response to gemcitabine in patients with advanced cholangiocarcinoma. Eur J Cancer48:990–996

5 Boswell-CasteelRC, HaysFA (2016) Equilibrative nucleoside transporters-A review. Nucleos Uucleot Nucl19:1–24

6 Boswell-CasteelRC, JohnsonJM, DugganKD, Roe-ZurzZ, SchmitzH, BurlesonC, HaysFA (2014) FUN26 (function unknown now 26) protein from Saccharomyces cerevisiae is a broad selectivity, high affinity, nucleoside and nucleobase transporter. J Biol Chem289:24440–24451

7 CatalaA, Pastor-AngladaM, Caviedes-CardenasL, MalatestaR, RivesS, Vega-GarciaN, CamosM, Fernandez-CalottiP (2016) FLT3 is implicated in cytarabine transport by human equilibrative nucleoside transporter 1 in pediatric acute leukemia. Oncotarget7:49786–49799

8 DengD, SunP, YanC, KeM, JiangX, XiongL, RenW, HirataK, YamamotoM, FanS(2015) Molecular basis of ligand recognition and transport by glucose transporters. Nature526:391–396

9 EndresCJ, UnadkatJD (2005) Residues Met89 and Ser160 in the human equilibrative nucleoside transporter 1 affect its affinity for adenosine, guanosine, S-6-(4-nitrobenzyl)-mercaptopurine riboside, and dipyridamole. Mol Pharmacol67:837–844

10 GiovannettiE, Del TaccaM, MeyV, FunelN, NannizziS, RicciS, OrlandiniC, BoggiU, CampaniD, Del ChiaroM (2006) Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. Cancer Res66:3928–3935

11 GovindarajanR, LeungGP, ZhouM, TseCM, WangJ, UnadkatJD (2009) Facilitated mitochondrial import of antiviral and anticancer nucleoside drugs by human equilibrative nucleoside transporter-3. Am J Physiol Gastrointest Liver Physiol296:G910–922

12 GrayJH, OwenRP, GiacominiKM (2004) The concentrative nucleoside transporter family, SLC28. Pflug Arch447:728–734

13 GriffithsM, BeaumontN, YaoSY, SundaramM, BoumahCE, DaviesA, KwongFY, CoeI, CassCE, YoungJD (1997a) Cloning of a human nucleoside transporter implicated in the cellular uptake of adenosine and chemotherapeutic drugs. Nat Med3:89–93

14 GriffithsM, YaoSYM, AbidiF, PhillipsSEV, CassCE, YoungJD, BaldwinSA (1997b) Molecular cloning and characterization of a nitrobenzylthioinosine-insensitive (ei) equilibrative nucleoside transporter from human placenta. Biochem J328:739–743

15 HydeRJ, CassCE, YoungJD, BaldwinSA (2001) The ENT family of eukaryote nucleoside and nucleobase transporters: recent advances in the investigation of structure/function relationships and the identification of novel isoforms. Mol Membr Biol18:53–63

16 JaakolaVP, GriffithMT, HansonMA, CherezovV, ChienEYT, LaneJR, IJzermanAP, StevensRC (2008) The 2.6 angstrom crystal structure of a human A(2A) adenosine receptor bound to an antagonist. Science322:1211–1217

17 JohnsonZL, CheongCG, LeeSY (2012) Crystal structure of a concentrative nucleoside transporter from Vibrio cholerae at 2.4 angstrom. Nature483:489–493

18 JohnsonZL, LeeJH, LeeKY, LeeMH, KwonDY, HongJY, LeeSY (2014) Structural basis of nucleoside and nucleoside drug selectivity by concentrative nucleoside transporters. Elife3: e36604

19 JordheimLP, DumontetC (2007) Review of recent studies on resistance to cytotoxic deoxynucleoside analogues. Biochim Biophys Acta1776:138–159

20 JordheimLP, DurantelD, ZoulimF, DumontetC (2013) Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases. Nat Rev Drug Discov12:447–464

21 KingAE, AckleyMA, CassCE, YoungJD, BaldwinSA (2006) Nucleoside transporters: from scavengers to novel therapeutic targets. Trends Pharmacol Sci27:416–425

22 KongW, EngelK, WangJ(2004) Mammalian nucleoside transporters. Curr Drug Metab5:63–84

23 LiM, HaysFA, Roe-ZurzZ, VuongL, KellyL, HoCM, RobbinsRM, PieperU, O’ConnellJD, MierckeLJW (2009) Selecting optimum eukaryotic integral membrane proteins for structure determination by rapid expression and solubilization screening. J Mol Biol385:820–830

24 MaJ, WangS, WangZ, XuJ (2015) Protein contact prediction by integrating joint evolutionary coupling analysis and supervised learning. Bioinformatics31:3506–3513

25 NordhS, AnsariD, AnderssonR (2014) hENT1 expression is predictive of gemcitabine outcome in pancreatic cancer: A systematic review. World J Gastroentero20:8482–8490

26 PaproskiRJ, VisserF, ZhangJ, TackaberryT, DamarajuV, BaldwinSA, YoungJD, CassCE (2008) Mutation of Trp29 of human equilibrative nucleoside transporter 1 alters affinity for coronary vasodilator drugs and nucleoside selectivity. Biochem J414:291–300

27 Pastor-AngladaM, Perez-TorrasS (2015) Nucleoside transporter proteins as biomarkers of drug responsiveness and drug targets. Front Pharmacol6:13

28 RehanS, JaakolaVP (2015) Expression, purification and functional characterization of human equilibrative nucleoside transporter subtype-1 (hENT1) protein from Sf9 insect cells. Protein Expres Purif114:99–107

29 RehanS, AshokY, NanekarR, JaakolaVP (2015) Thermodynamics and kinetics of inhibitor binding to human equilibrative nucleoside transporter subtype-1. Biochem Pharmacol98:681–689

30 ReyesG, NaydenovaZ, AbdullaP, ChalsevM, VillaniA, RoseJB, ChaudaryN, DeSouzaL, SiuKW, CoeIR (2010) Characterization of mammalian equilibrative nucleoside transporters (ENTs) by mass spectrometry. Protein Expr Purif73:1–9

31 ReyesG, NivillacNM, ChalsevM, CoeIR (2011) Analysis of recombinant tagged equilibrative nucleoside transporter 1 (ENT1) expressed in E. coli. Biochem Cell Biol89:246–255

32 SenGuptaDJ, UnadkatJD (2004) Glycine 154 of the equilibrative nucleoside transporter, hENT1, is important for nucleoside transport and for conferring sensitivity to the inhibitors nitrobenzylthioinosine, dipyridamole, and dilazep. Biochem Pharmacol67:453–458

33 SenGuptaDJ, LumPY, LaiY, ShubochkinaE, BakkenAH, SchneiderG, UnadkatJD (2002) A single glycine mutation in the equilibrative nucleoside transporter gene, hENT1, alters nucleoside transport activity and sensitivity to nitrobenzylthioinosine. Biochemistry41:1512–1519

34 SundaramM, YaoSYM, IngramJC, BerryZA, AbidiF, CassCE, BaldwinSA, YoungJD (2001) Topology of a human equilibrative, nitrobenzylthioinosine (NBMPR)-sensitive nucleoside transporter (hENT1) implicated in the cellular uptake of adenosine and anticancer drugs. J Biol Chem276:45270–45275

35 SvrcekM, CrosJ, MarechalR, BachetJB, FlejouJF, DemetterP (2015) Human equilibrative nucleoside transporter 1 testing in pancreatic ductal adenocarcinoma: a comparison between murine and rabbit antibodies. Histopathology66:457–462

36 ValdesR, Arastu-KapurS, LandfearSM, ShindeU (2009) An ab Initio structural model of a nucleoside permease predicts functionally important residues. J Biol Chem284:19067–19076

37 ValdesR, ElferichJ, ShindeU, LandfearSM (2014) Identification of the intracellular gate for a member of the equilibrative nucleoside transporter (ENT) family. J Biol Chem289:8799–8809

38 VickersMF, ManiRS, SundaramM, HogueDL, YoungJD, BaldwinSA, CassCE (1999) Functional production and reconstitution of the human equilibrative nucleoside transporter (hENT1) in Saccharomyces cerevisiae—interaction of inhibitors of nucleoside transport with recombinant hENT1 and a glycosylationdefective derivative (hENT1/N48Q). Biochem J339:21–32

39 VisserF, VickersMF, NgAM, BaldwinSA, YoungJD, CassCE (2002)Mutation of residue 33 of human equilibrative nucleoside transporters 1 and 2 alters sensitivity to inhibition of transport by dilazep and dipyridamole. J Biol Chem277:395–401

40 VisserF, ZhangJ, RabornRT, BaldwinSA, YoungJD, CassCE (2005) Residue 33 of human equilibrative nucleoside transporter 2 is a functionally important component of both the dipyridamole and nucleoside binding sites. Mol Pharmacol67:1291–1298

41 VisserF, SunL, DamarajuV, TackaberryT, PengY, RobinsMJ, BaldwinSA, YoungJD, CassCE (2007) Residues 334 and 338 in transmembrane segment 8 of human equilibrative nucleoside transporter 1 are important determinants of inhibitor sensitivity, protein folding, and catalytic turnover.J Biol Chem282:14148–14157

42 WallMJ, RichardsonMJ (2015) Localized adenosine signaling provides fine-tuned negative feedback over a wide dynamic range of neocortical network activities. J Neurophysiol113:871–882

43 WangZ, XuJ (2013) Predicting protein contact map using evolutionary and physical constraints by integer programming. Bioinformatics29:i266–273

44 WangS, LiW, ZhangR, LiuS, XuJ (2016) CoinFold: a web server for protein contact prediction and contact-assisted protein folding. Nucleic Acids Res44:W361–366

45 WardJL, SheraliA, MoZP, TseCM (2000) Kinetic and pharmacological properties of cloned human equilibrative nucleoside transporters, ENT1 and ENT2, stably expressed in nucleoside transporter-deficient PK15 cells. Ent2 exhibits a low affinity for guanosine and cytidine but a high affinity for inosine. J Biol Chem275:8375–8381

46 WrightAM, GatiWP, PatersonAR (2000) Enhancement of retention and cytotoxicity of 2-chlorodeoxyadenosine in cultured human leukemic lymphoblasts by nitrobenzylthioinosine, an inhibitor of equilibrative nucleoside transport. Leukemia14:52–60

47 YaoSYM, SundaramM, ChomeyEG, CassCE, BaldwinSA, YoungJD (2001) Identification of Cys(140) in helix 4 as an exofacial cysteine residue within the substrate-translocation channel of rat equilibrative nitrobenzylthioinosine (NBMPR)-insensitive nucleoside transporter rENT2. Biochem J353:387–393

48 YaoSYM, NgAML, VickersMF, SundaramM, CassEC, BaldwinSA, YoungJD (2002) Functional and molecular characterization of nucleobase transport by recombinant human and rat equilibrative nucleoside transporters 1 and 2—chimeric constructs reveal a role for the ENT2 helix 5-6 region in nucleobase translocation. J Biol Chem277:24938–24948

49 YaoSYM, NgAML, CassCE, BaldwinSA, YoungJD (2011) Nucleobase transport by human equilibrative nucleoside transporter 1 (hENT1). J Biol Chem286:32552–32562

50 YoungJD (2016) The SLC28 (CNT) and SLC29 (ENT) nucleoside transporter families: a 30-year collaborative odyssey. Biochem Soc Trans44:869–876

51 YoungJD, YaoSYM, BaldwinJM, CassCE, BaldwinSA (2013) The human concentrative and equilibrative nucleoside transporter families, SLC28 and SLC29. Mol Aspects Med34:529–547